Regulation by PGE₂ of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts

*¹Hideo Inoue, ¹Makiko Takamori, ¹Yoshihito Shimoyama, ²Hideaki Ishibashi, ²Seizo Yamamoto & ³Yasuko Koshihara

¹Research Laboratory, Minophagen Pharmaceutical Co., 2-2-3 Komatsubara, Zama-shi, Kanagawa 228-0002, Japan;

²Department of Orthopedic Surgery, Tokyo Metropolitan Geriatric Hospital, Itabashi-ku, Tokyo 173-0015, Japan and

³Department of Nutrition, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan

1 We examined the effects of endogenous prostaglandin E₂ (PGE₂) on the production of interleukin-6 (IL-6), macrophage colony stimulating factor (M-CSF), and vascular endothelial growth factor (VEGF) by interleukin-1 β (IL-1 β)-stimulated human synovial fibroblasts.

2 NS-398 (1 μ M), a cyclo-oxygenase-2 (COX-2) inhibitor, inhibited IL-6 and VEGF production (35 $\pm$ 4% and 26 $\pm$ 2%, respectively) but enhanced M-CSF production (38 $\pm$ 4%) by IL-1 β (1 ng ml⁻¹) in synovial fibroblasts isolated from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Exogenous PGE₂ completely abolished the effects of NS-398 on the production of each mediator by OA fibroblasts stimulated with IL-1 β .

3 8-Bromo cyclic AMP and dibutyryl cyclic AMP, cyclic AMP analogues, mimicked the effects of PGE₂ on IL-6, M-CSF, and VEGF production by OA fibroblasts.

4 The EP₂ selective receptor agonist ONO-AE1-259 (2 nM) and the EP₄ selective receptor agonist ONO-AE1-329 (2 or 20 nM), but not the EP₁ selective receptor agonist ONO-DI-004 (1 μ M) and the EP₃ selective receptor agonist ONO-AE-248 (1 μ M), replaced the effects of PGE₂ on IL-6, M-CSF, and VEGF production by OA and RA fibroblasts stimulated with IL-1 β in the presence of NS-398.

5 Both OA and RA fibroblasts expressed mRNA encoding EP₂ and EP₄ but not EP₁ receptors. In addition, up-regulation of EP₂ and EP₄ receptor mRNAs was observed at 3 h after IL-1 β treatment.

6 These results suggest that endogenous PGE₂ regulates the production of IL-6, M-CSF, and VEGF by IL-1 β -stimulated human synovial fibroblasts through the activation of EP₂ and EP₄ receptors with increase in cyclic AMP.

British Journal of Pharmacology (2002) **136**, 287–295

Keywords: Synovial fibroblasts; PGE₂; EP receptor subtypes; EP receptor agonists; IL-6; M-CSF; VEGF; rheumatoid arthritis; osteoarthritis

Abbreviations: COX, cyclo-oxygenase; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FCS, foetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GM-CSF, granulocyte macrophage-colony stimulating factor; IL, interleukin; M-CSF, macrophage colony stimulating factor; OA, osteoarthritis; PGE₂, prostaglandin E₂; RA, rheumatoid arthritis; RT-PCR, reverse transcription–polymerase chain reaction; TNF- α , tumour necrosis factor- α ; VEGF, vascular endothelial growth factor; α -MEM, α -minimum essential medium

Introduction

The inflammatory process is a complex mechanism, orchestrated by both infiltrating cells and mesenchymally derived cells. Pro-inflammatory cytokines are considered to play important roles in the initiation and development of joint diseases, including RA and OA (Feldmann *et al.*, 1996; Westacott & Sharif, 1996; Isomaki & Punnonen, 1997). IL-1, as well as tumour necrosis factor- α (TNF- α), is the most prominent cytokine for developing synovial inflammation and plays a predominant role in the etiopathology of joint disease. It has been established that IL-1 enhances synovial fibroblast DNA synthesis (Butler *et al.*, 1988) and activates synovial cells to secrete soluble mediators such as collagenase

(Dayer *et al.*, 1986), PGE₂ (Dayer *et al.*, 1986), IL-6 (Guerne *et al.*, 1989), and VEGF (Jackson *et al.*, 1997). These mediators are involved in inflammatory response, joint destruction, and angiogenesis. PGs and related eicosanoids also contribute to inflammatory responses in joint diseases (Robinson *et al.*, 1975). PG production is mediated by two isoforms of cyclo-oxygenase (COX) (DeWitt, 1991; Xie *et al.*, 1991), a constitutive form (COX-1), and an inducible form (COX-2). The induction of COX-2 by IL-1 β in synovial cells is associated with an increase in PGE₂ production (Crofford *et al.*, 1994; Hulkower *et al.*, 1994). In addition, the expression of COX-2 is elevated in a disease-related pattern of synovial tissue from patients with arthritis (Siegle *et al.*, 1998).

PGE₂ is able to control the production of diverse chemical mediators in various cells. While PGE₂ induces VEGF

*Author for correspondence;
E-mail: inoue@lab.minophagen.co.jp

expression in RA synovial fibroblasts (Ben-Av *et al.*, 1995) and human prostate cancer cells (Liu *et al.*, 1999), it reduces TNF- α production by rodent macrophages (Kunkel *et al.*, 1988) and M-CSF production by human monocytes (Lee *et al.*, 1990). We previously reported that PGE₂ induces the production of parathyroid hormone-related peptide in OA synovial fibroblasts (Yoshida *et al.*, 1998). Furthermore, PGE₂ is suggested to regulate the production of cytokines such as IL-6, IL-8, IL-11, and granulocyte macrophage colony stimulating factor (GM-CSF) by IL-1-stimulated synovial fibroblasts (Agro *et al.*, 1996; Mino *et al.*, 1998). However, it is not well understood whether endogenous PGE₂ participates in the production of soluble factors by human synovial fibroblasts through PGE₂ receptors.

The physiological and pharmacological actions of PGE₂ on cell growth and function are mediated by a specific group of seven transmembrane receptors. PGE₂ receptors have been classified into four subtypes, designated the EP₁, EP₂, EP₃, and EP₄ receptors (Coleman *et al.*, 1994; Negishi *et al.*, 1995). EP₁ receptors associate phospholipase C and phosphoinositol turnover, and stimulate the release of intracellular calcium. EP₂ and EP₄ receptors increase cyclic AMP levels *via* activation of adenylate cyclase, whereas EP₃ receptor variants mediate multiple signal pathways such as inhibition or stimulation of cyclic AMP levels, activation of phospholipase C, and mobilization of intracellular calcium. Recently, the prostanoid derivative EP receptor agonists such as ONO-DI-004 for EP₁, ONO-AE1-259 for EP₂, ONO-AE-248 for EP₃, and ONO-AE1-329 for EP₄ (Figure 1) have been developed (Suzawa *et al.*, 2000) and used to examine the role and function of PGE₂ receptor subtypes (Zacharowski *et al.*, 1999; Suzawa *et al.*, 2000; Yamane *et al.*, 2000). We report here, for the first time, that endogenous PGE₂ regulates the production of IL-6, VEGF, and M-CSF by IL-1 β in synovial fibroblasts obtained from patients with OA and RA through

the activation of EP₂ and EP₄ receptors. Furthermore, the results from this study favour the hypothesis that PGE₂ plays an important role as a regulator in the production of chemical mediators driven inflammation.

Methods

Reagents

Recombinant human IL-1 β was purchased from Becton Dickinson Labware (Bedford, MA, U.S.A.). PGE₂ and pentoxifylline were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 8-Bromo cyclicAMP and dibutyryl cyclic AMP were purchased from Biomol Research Laboratory (Plymouth Meeting, PA, U.S.A.), and NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulphonamide) was purchased from Cayman Chemical Co. (Ann Arbor, MI, U.S.A.). ONO-DI-004 ((17S)-2,5-ethano-6-oxo-17,20-dimethylPGE₁), ONO-AE1-259((16S)-9-deoxy-9 β -chloro-15-deoxy-16-hydroxy-17, 17-trimethylene-19, 20-didehydroPGE₂ sodium salt), ONO-AE-248 (11, 15-O-dimethylPGE₂), and ONO-AE1-329 (16-(3-methoxymethyl)phenyl- ω -tetranor-3, 7-dithiaPGE₁) were generous gifts from Ono Pharmaceutical Co. (Osaka, Japan).

Synovial fibroblast culture

Primary cultures of human synovial fibroblasts were obtained by enzymatic digestion of synovial tissue obtained from patients with OA and RA (Takayanagi *et al.*, 1997). Fibroblasts were cultured in α -minimum essential medium (α -MEM; Gibco BRL, Gaithersburg, MD, U.S.A.) containing heat-inactivated 10% foetal calf serum (FCS) (Biowhitaker, Walkersville, MD, U.S.A.) and 60 μ g ml⁻¹ kanamycin

Figure 1 Chemical structures of ONO-DI-004, ONO-AE1-259, ONO-AE-248, and ONO-AE1-329.

Table 1 Gene-specific primer sequences used in PCR amplification

Gene		Primer sequence	Product size, bp
EP ₁ receptor	Sense	5'-CTCGCCGCGCTGGTGTGCAACACGC-3'	519
	Antisense	5'-GGCCTCCCAGGCGCTCGGTGTTAGGCC-3'	
EP ₂ receptor	Sense	5'-TTCATCCGGCACGGGCGGACCGC-3'	510
	Antisense	5'-GTCAGCCTGTTTACTGGCATCTG-3'	
EP ₃ receptor	Sense	5'-CGTGTGCGCGAGCTACCGGCG-3'	398
	Antisense	5'-CGGGCCACTGGACGGTGTACT-3'	
EP ₄ receptor	Sense	5'-CCTCCTGAGAAAGACAGTGCT-3'	366
	Antisense	5'-AAGACACTCTCTGAGTCCT-3'	

sulphate (Gibco BRL) at 37°C in a humidified atmosphere of 95% air and 5% CO₂. The culture medium was replaced twice each week. The confluent cells were dispersed with trypsinization and then transferred to new plastic dishes in a split ratio of 1:2 or 1:4. The cells at more than six passages (eight population doubling levels, PDL) were used for subsequent experiments. These cells consisted of fibroblasts alone, with no dendritic or monocytic cells.

Synovial fibroblasts were plated onto 24-well plates (Becton Dickinson Labware) at 2×10^4 cells ml⁻¹ to perform the experiments. When cells grew up to confluence, cells were kept in 0.5 ml α -MEM containing 0.5% FCS for 48 h and then exposed to a concentration of 1 ng ml⁻¹ IL-1 β (Inoue *et al.*, 2001) in the presence or absence of different agents dissolved in DMSO (0.1%) for 24 h. Each study was repeated another one or two times.

Measurement of IL-6, IL-8, M-CSF, PGE₂, and VEGF levels in the culture medium

The culture media were collected at 24 h after IL-1 β stimulation and kept at -80°C until used for assay. Concentrations of IL-6 (detection limit: 3 pg ml⁻¹), M-CSF (detection limit: 9 pg ml⁻¹), PGE₂ (detection limit roughly 12 pg ml⁻¹), and VEGF (detection limit: 5 pg ml⁻¹) in the culture supernatant were measured directly by the enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's directions. ELISA kits used were purchased from PerSeptive Biosystems (Framingham, MA, U.S.A.) for IL-6, R & D systems (Minneapolis, MN, U.S.A.) for M-CSF and VEGF, and Cayman Chemical for PGE₂. Sample and standard dilutions were made with experimental medium, and results were expressed as the mean $\pm$ s.e.m. The statistical significance was determined with the Tukey-Kramer multiple comparison test after one-way analysis of variance. Appropriate groups were compared by Student's *t*-test.

RT-PCR analysis of EP receptor subtypes

Total RNA was extracted from synovial fibroblasts (10⁶ cells) by acid guanidine-phenol-chloroform extraction using ISOGEN[®] (Nippon Gene, Toyama, Japan) and treated with a DNA-free kit (Ambion, Austin, TX, U.S.A.) for elimination of contaminating DNA. cDNA was synthesized from isolated RNA with oligo-dT primer and AMV reverse transcriptase XL (TaKaRa RNA PCR kit (AMV) Ver. 2.1, Takara, Osaka, Japan), and used as templates for PCR. PCR for EP₂ and EP₄ receptors was carried out for 30–32 cycles of 95°C for 1 min, 58°C for 1 min, and 72°C for

1 min, followed by a final of 72°C for 6 min. That for EP₁ and EP₃ receptors was performed for 42 cycles of 95°C for 1 min, 65°C for 1 min, and 72°C for 1 min, followed by a final of 72°C for 6 min. The synthetic primers for the human PGE₂ receptors were designed to according to Zeng *et al.* (1998) (Table 1). The constitutively expressed gene encoding GAPDH was used as internal control in RT-PCR to normalize the amounts of mRNA in each sample. The cDNA of the GAPDH gene was amplified from the same volume of cDNAs as for EP receptors, but only 10–12 cycles of PCR. The PCR products were analysed by electrophoresis in a 2% agarose gel visualized using ethidium bromide. No PCR product was amplified without reverse-transcription reaction.

Results

Effects of exogenous PGE₂ on the spontaneous production of IL-6, M-CSF, and VEGF by OA fibroblasts

We first examined whether PGE₂ alone affects the spontaneous release of IL-6, M-CSF, and VEGF from OA fibroblasts (Table 2). OA fibroblasts themselves released immunoreactive IL-6, M-CSF, and VEGF for 24 h culture without any stimulants. Among them, spontaneous level of M-CSF was higher than that of IL-6 and VEGF. PGE₂ dose-dependently increased the secretion of IL-6 and VEGF from OA fibroblasts. When cells were treated with 1 ng ml⁻¹ PGE₂, significant ($P < 0.05$) increases in the release of IL-6 and VEGF were observed. Also, levels of IL-6 and VEGF were further enhanced a 12 and 2 fold by 20 ng ml⁻¹ PGE₂, respectively, compared with PGE₂-untreated cells. In contrast, PGE₂ at a concentration of 20 ng ml⁻¹ significantly ($P < 0.05$) decreased M-CSF level.

Effects of exogenous PGE₂ on IL-6, M-CSF, and VEGF production by OA fibroblasts stimulated with IL-1 β in the presence of NS-398

We had recently reported that IL-1 β induced the production of IL-6, M-CSF, PGE₂, and VEGF in synovial fibroblasts of patients with OA and RA (Inoue *et al.*, 2001). In fact, IL-1 β (1 ng ml⁻¹) markedly increased IL-6, M-CSF, and VEGF production by OA synovial fibroblasts (Figure 2). Basal levels of IL-6, M-CSF, and VEGF were 119 ± 4 , 540 ± 7 , and 120 ± 5 pg ml⁻¹ ($n = 5-6$), respectively. Increase in IL-6 production by IL-1 β was greater than that in M-CSF and VEGF production. The release of PGE₂ was also enhanced significantly ($P < 0.001$, Student's *t*-test) by IL-1 β from the

Table 2 Effects of exogenous PGE₂ on the spontaneous production of IL-6, M-CSF, and VEGF by OA synovial fibroblasts

Dose (ng ml ⁻¹)	IL-6 (pg ml ⁻¹)	M-CSF (pg ml ⁻¹)	VEGF (pg ml ⁻¹)
PGE ₂ 0	150 ± 8	581 ± 31	101 ± 2
1	230 ± 8*	625 ± 30	122 ± 3*
10	930 ± 4**	523 ± 27	175 ± 5**
20	1740 ± 4**	481 ± 8*	196 ± 10**

Confluent fibroblasts were treated with PGE₂ at a concentration of 1, 10 or 20 ng ml⁻¹ for 24 h. The result represents the mean ± s.e.m. of 5–6 samples. **P* < 0.05 or ***P* < 0.01 vs control (PGE₂:0) (Tukey–Kramer multiple test).

Figure 2 Effects of exogenous PGE₂ on IL-6, M-CSF, and VEGF production by OA synovial fibroblasts stimulated with IL-1β in the presence of NS-398. Confluent fibroblasts were treated with IL-1β (1 ng ml⁻¹) in the presence or absence of NS-398 (1 μM) and PGE₂ at various concentrations for 24 h. +: with and -: without. Values are the mean ± s.e.m. of 5–6 samples. **P* < 0.05 or ***P* < 0.01 vs IL-1β (Student's *t*-test). † *P* < 0.01 vs IL-1β + NS-398 (Tukey–Kramer multiple test).

basal value 0.030 ± 0.003 to 8.1 ± 0.5 ng ml⁻¹ (*n* = 6). NS-398, a COX-2 inhibitor (Futaki *et al.*, 1994), at a dose of 1 μM which completely blocks the production of PGE₂ in this model (Inoue *et al.*, 2001), significantly (*P* < 0.01 or *P* < 0.001) inhibited IL-6 and VEGF production. In contrast, treatment with NS-398 resulted in approximately 30% increase in M-CSF production compared with IL-1β alone value. Furthermore, treatment of OA fibroblasts with PGE₂ completely abolished the effects of NS-398 on IL-1β-induced IL-6, M-CSF, and VEGF production. Simultaneous addition of 10 or 20 ng ml⁻¹ PGE₂ to IL-1β resulted in further enhancement of IL-6 and VEGF production in the presence of NS-398. Contrary, PGE₂ dose-dependently inhibited the enhancement by NS-398 of IL-1β-induced M-CSF production. M-CSF level increased in response to IL-1β was significantly (*P* < 0.01) reduced up to 64% by 20 ng ml⁻¹ PGE₂.

Involvement of cyclic AMP in the production of IL-6, M-CSF, and VEGF by OA fibroblasts stimulated with IL-1β

Effects of cyclic AMP analogues were examined on IL-6, M-CSF, and VEGF production by IL-1β in OA fibroblasts. 8-Bromo-cyclic AMP and dibutyryl-cyclic AMP, cyclic AMP analogues, at 1 mM significantly (*P* < 0.01, Student's *t*-test) increased the basal level of IL-6 from 84 ± 3 to 2490 ± 260 and 2364 ± 54 pg ml⁻¹ (*n* = 5), and of VEGF from 115 ± 3 to 289 ± 14 and 340 ± 5 pg ml⁻¹ (*n* = 5), respectively. In contrast, 8-bromo-cyclic AMP and dibutyryl-cyclic AMP markedly (*P* < 0.01, Student's *t*-test) reduced the basal level of M-CSF from 509 ± 8 to 288 ± 11 and 344 ± 12 pg ml⁻¹ (*n* = 5), respectively. Both compounds dose-dependently enhanced IL-1β-induced IL-6 and VEGF production in the presence of NS-398 (Figure 3). However, dibutyryl-cyclic AMP at a high dose (1 mM) failed to enhance IL-6 production. 8-Bromo-cyclic AMP and dibutyryl-cyclic AMP significantly (*P* < 0.01) inhibited M-CSF production by IL-1β in a dose-dependent manner. Furthermore, pentoxifylline (0.5 mM), a non-selective phosphodiesterase inhibitor (Ward & Clissold, 1987), significantly (*P* < 0.05, Student's *t*-test) enhanced VEGF production in response to IL-1β (IL-1β: 583 ± 31 vs pentoxifylline: 695 ± 29 pg ml⁻¹, *n* = 5) whereas it markedly (*P* < 0.01, Student's *t*-test) reduced IL-1β-induced M-CSF production (IL-1β: 1992 ± 47 vs pentoxifylline: 1647 ± 36 pg ml⁻¹, *n* = 5).

Effects of EP receptor agonists on IL-6, M-CSF, and VEGF production by IL-1β in OA and RA fibroblasts

We next determined whether PGE₂ regulates IL-1β-stimulated IL-6, M-CSF, and VEGF production via PGE₂ receptor subtypes by employing selective EP receptor agonists such as ONO-DI-004, ONO-AE1-259, ONO-AE1-248, and ONO-AE1-329. The specificities of the agonists have been confirmed by the binding assay for the respective receptor subtypes expressed in CHO cells (Suzawa *et al.*, 2000). In addition, ONO-AE1-259 and ONO-AE1-329 have no difference in binding affinity and agonist activity between mouse and human EP receptors (personal communications). Basal levels of IL-6, M-CSF, and VEGF in OA fibroblasts were 107 ± 12 , 527 ± 13 , and 120 ± 7 pg ml⁻¹ (*n* = 5–6), respectively. Similar to the exogenous PGE₂, the EP₂ receptor agonist ONO-AE1-259 and the EP₄ receptor agonist ONO-AE1-329 at a dose of 2 or 20 nM not only enhanced the production of IL-6 and VEGF but also reduced M-CSF production by OA fibroblasts treated with IL-1β in the presence of NS-398 (Table 3). However, the EP₁ receptor agonist ONO-DI-004 and the EP₃ receptor agonist ONO-AE1-248 had no effect on the production of each mediator until 1 μM. Both agonists for EP₂ and EP₄ receptors, as well as PGE₂, enhanced spontaneous levels of IL-6 and VEGF, and attenuated spontaneous M-CSF level in non-stimulated OA fibroblasts (data not shown).

Furthermore, we examined the effects of EP receptor agonists on IL-1β-induced IL-6, M-CSF, and VEGF production in RA synovial fibroblasts (Table 4). Basal levels of IL-6, M-CSF, and VEGF were 202 ± 7 , 357 ± 9 , and 69 ± 4 pg ml⁻¹ (*n* = 5–6), respectively. Similar to OA fibroblasts, basal level of M-CSF was higher than that of IL-6 and VEGF in RA fibroblasts. In addition, IL-1β strongly induced

Figure 3 Effects of cyclic AMP analogues on IL-6, M-CSF, and VEGF production by OA synovial fibroblasts stimulated with IL-1β in the presence of NS-398. Confluent fibroblasts were treated with IL-1β (1 ng ml⁻¹) in the presence or absence of NS-398 (1 μM) and dibutyryl-cyclic AMP (dbcAMP) or 8-bromo-cyclic AMP (8brcAMP) at various concentrations for 24 h. +: with and -: without. Values are the mean ± s.e.m. of 5–6 samples. **P* < 0.05 or ***P* < 0.01 vs IL-1β (Student's *t*-test). †*P* < 0.01 vs IL-1β + NS-398 (Tukey–Kramer multiple test).

Table 3 Effects of EP receptor agonists on IL-1β-induced IL-6, M-CSF, and VEGF production in OA synovial fibroblasts

	IL-6 (ng ml ⁻¹)	M-CSF (pg ml ⁻¹)	VEGF (pg ml ⁻¹)
IL-1β	153 ± 8	2164 ± 86	457 ± 11
IL-1β + NS-398	93 ± 9**	3260 ± 50***	347 ± 34*
IL-1β + NS-398 ± EP ₁ agonist			
ONO-DI-004 (μM)			
0.2	97 ± 5	3184 ± 61	318 ± 26
1.0	98 ± 8	3195 ± 98	352 ± 11
IL-1β + NS-398 ± EP ₃ agonist			
ONO-AE-248 (μM)			
0.2	92 ± 1	3049 ± 29	350 ± 11
1.0	87 ± 2	3188 ± 69	339 ± 7
IL-1β	168 ± 5	2334 ± 127	457 ± 11
IL-1β + NS-398	116 ± 11**	3257 ± 149**	347 ± 34*
IL-1β + NS-398 ± EP ₂ agonist			
ONO-AE1-259 (nM)			
0.02	116 ± 5	2905 ± 48	335 ± 32
2.0	166 ± 6††	2281 ± 76††	469 ± 15†
IL-1β + NS-398 ± EP ₄ agonist			
ONO-AE1-329 (nM)			
0.02	108 ± 3	2714 ± 64††	319 ± 9
2.0	176 ± 20†	2783 ± 75†	429 ± 11
20.0	175 ± 7††	2267 ± 5††	472 ± 29††

Confluent fibroblasts were treated with IL-1β (1 ng ml⁻¹) in the presence or absence of NS-398 (1 μM) and EP receptor agonists at various concentrations for 24 h. The result represents the mean ± s.e.m. of 5–6 samples. **P* < 0.05, ***P* < 0.01 or ****P* < 0.001 vs IL-1β (Student's *t*-test). †*P* < 0.05 or ††*P* < 0.01 vs IL-1β + NS-398 (Tukey–Kramer multiple test).

IL-6 production compared with M-CSF and VEGF production. IL-6 and VEGF production in response to IL-1β were inhibited, but M-CSF production was enhanced by treatment with NS-398. In OA and RA fibroblasts, inhibition by NS-398 of IL-1β-induced IL-6 and VEGF production was

35 ± 4% and 26 ± 2% (*n* = 4–5 experiments), respectively, whereas enhancement of M-CSF was 38 ± 4% (*n* = 5 experiments). As expected, the EP₂ receptor agonist ONO-AE1-259 and the EP₄ receptor agonist ONO-AE1-329 at a dose of 2 nM were effective in enhancing IL-6 and VEGF production,

Table 4 Effects of EP receptor agonists on IL-1 β -induced IL-6, M-CSF, and VEGF production in RA synovial fibroblasts

	IL-6 (ng ml ⁻¹)	M-CSF (pg ml ⁻¹)	VEGF (pg ml ⁻¹)
IL-1 β	134 $\pm$ 4	2367 $\pm$ 105	301 $\pm$ 13
IL-1 β + NS-398	96 $\pm$ 4***	3123 $\pm$ 187**	219 $\pm$ 18**
IL-1 β + NS-398 + EP ₁ agonist ONO-DI-004 (μ M)			
0.2	108 $\pm$ 3	2825 $\pm$ 75	230 $\pm$ 3
1.0	112 $\pm$ 1	3012 $\pm$ 143	229 $\pm$ 7
IL-1 β + NS-398 + EP ₃ agonist ONO-AE-248 (μ M)			
0.2	103 $\pm$ 6	3701 $\pm$ 112†	199 $\pm$ 7
1.0	119 $\pm$ 2	2817 $\pm$ 87	237 $\pm$ 8
IL-1 β + NS-398 + EP ₂ agonist ONO-AE1-259 (nM)			
0.02	99 $\pm$ 1	2948 $\pm$ 67	212 $\pm$ 5
2.0	139 $\pm$ 12††	1567 $\pm$ 97††	300 $\pm$ 8††
IL-1 β + NS-398 + EP ₄ agonist ONO-AE1-329 (nM)			
0.02	93 $\pm$ 8	3638 $\pm$ 35†	206 $\pm$ 5
2.0	136 $\pm$ 11†	2058 $\pm$ 129††	281 $\pm$ 7††

Confluent fibroblasts were treated with IL-1 β (1 ng ml⁻¹) in the presence or absence of NS-398 (1 μ M) and EP receptor agonists at various concentrations for 24 h. The result represents the mean $\pm$ s.e.m. of 5–6 samples. * P < 0.01 or *** P < 0.001 vs IL-1 β (Student's *t*-text). † P < 0.05 or †† P < 0.01 vs IL-1 β + NS-398 (Tukey–Kramer multiple test).

and in inhibiting M-CSF production by IL-1 β -stimulated RA fibroblasts. In contrast to this, EP₁ and EP₃ receptor agonists at 1 μ M did not change the production of IL-6, M-CSF, and VEGF by IL-1 β in the presence of NS-398. EP₂ receptor agonist effectively attenuated M-CSF production compared with EP₄ receptor agonist in both OA and RA fibroblasts.

Enhancement by IL-1 β of EP₂ and EP₄ receptor mRNAs in OA and RA fibroblasts

As EP₂ and EP₄ receptors were suggested to be involved in the production of IL-6, M-CSF, and VEGF by IL-1 β , we examined expression of mRNA encoding EP receptor subtypes in OA and RA synovial fibroblasts by RT–PCR. Co-expression of EP₂, EP₃, and EP₄ receptor mRNAs was confirmed in total RNA isolated from OA fibroblasts (Figure 4a, lane 1). Expression of EP₂, EP₃, and EP₄ receptor mRNAs was up-regulated at up to 3 h after IL-1 β stimulation (Figure 4a, lane 3). As shown in Figure 4b, mRNA encoding EP₂ and EP₄ receptors was confirmed in RA fibroblasts (Figure 4b, lane 1) and up regulated at 3 h after IL-1 β stimulation (Figure 4b, lane 2). EP₃ receptor mRNA was not observed in either IL-1 β -treated or -untreated RA fibroblasts. Nevertheless, RA fibroblasts derived from other donors expressed EP₃ receptor mRNA as well as EP₂ and EP₄ receptor mRNAs (data not shown). Expression of EP₁ receptor mRNA was not observed in both OA and RA fibroblasts, and induced even by treatment with IL-1 β (data not shown).

Discussion

In this study, we have presented evidence showing that endogenous PGE₂ regulates the production of IL-6, M-CSF, and VEGF in response to IL-1 β through the activation of

Figure 4 Time-course of mRNA encoding PGE₂ receptor subtypes in OA (a) and RA (b) synovial fibroblasts treated with IL-1 β . Total RNA was isolated from confluent fibroblasts at 1, 3, 6, 12 or 24 h after IL-1 β (1 ng ml⁻¹) treatment and subjected to RT–PCR with a specific primer for each EP receptor or GAPDH. After RT–PCR, amplified products were analysed by agarose gel electrophoresis with ethidium bromide staining. The cultures without IL-1 β treatment served as the control. (a) Lane 1: control; lane 2: 1 h; lane 3: 3 h; lane 4: 6 h; lane 5: 12 h; lane 6: 24 h. (b) Lane 1: control; lane 2: 3 h. The figure was one representative of three independent experiments.

EP₂ and EP₄ receptors in human synovial fibroblasts. Synovial fluid of patients with RA and OA contains many soluble mediators, such as cytokines and growth factors, which contribute to the development of joint diseases (Feldmann *et al.*, 1996; Westacott & Sharif, 1996). IL-6 increases B-cell proliferation, immunoglobulin production,

and acute phase protein production, and may stimulate rheumatoid factor secretion in the synovium (Isomaki & Punnonen, 1997). M-CSF, as well as granulocyte macrophage-colony stimulating factor (GM-CSF), activates monocytes/macrophages to produce cytokines and increases the number of mature macrophages in the inflamed synovium (Moss & Hamilton, 2000). VEGF plays an important role of angiogenesis and endothelial migration during development of RA synovitis (Folkman, 1995; Nagashima *et al.*, 1995). In addition, inflammatory mediators including cytokines and PGs are also involved in the induction of angiogenesis (Fidler & Ellis, 1994). In our study, the COX-2 inhibitor NS-398 inhibited IL-6 and VEGF production as well as PGE₂ production in response to IL-1 β whereas it enhanced M-CSF production in synovial fibroblasts, suggesting that autocrine stimulation by PGs is involved in the production of them. In fact, exogenous PGE₂ abolished the effect of NS-398 in response to IL-1 β . PGE₂ also potentiated the spontaneous production of IL-6 and VEGF, and attenuated M-CSF production by non-stimulated synovial fibroblasts. However, the ability of PGE₂ to produce IL-6 and VEGF was low compared with IL-1 β . Thus, endogenous PGE₂ seems to play as a promoter in the production of cytokine and growth factor by synovial fibroblasts stimulated with IL-1 β . Others have found that PGE₂ enhances IL-6 production but inhibits GM-CSF production by IL-1 α -stimulated human synovial fibroblasts (Agro *et al.*, 1996). IL-11, a functionally pleiotropic cytokine classified as an IL-6-type cytokine, produced by RA fibroblasts treated with IL-1 α and TNF- α is inhibited by indomethacin, and its inhibition is prevented by PGE₂ treatment (Mino *et al.*, 1998). Furthermore, PGE₂ participates in the upregulation of VEGF by cobalt chloride-stimulated hypoxia in human prostate cancer cells (Liu *et al.*, 1999). Taken together, our results indicate that endogenous PGE₂ regulates the production of IL-6, M-CSF, and VEGF by IL-1 β in synovial fibroblasts derived from arthritis. In addition to PGE₂, other prostanoids also might modulate the production of cytokine and growth factor in response to IL-1 β , as suggested by others that prostacyclin regulates the release of GM-CSF and granulocyte-colony stimulating factor from human vascular smooth muscle cells stimulated with IL-1 β (Stanford *et al.*, 2000).

It has been reported that human synovial fibroblasts express mRNA encoding the EP₁ and EP₂ subtypes of PGE₂ receptors (Ben-Av *et al.*, 1995). We confirmed that both OA and RA fibroblasts express EP₂, EP₃, and EP₄, but not EP₁, receptor mRNAs, although there was difference in expression of EP₃ receptor mRNA between RA donors. A recent report has shown that RA fibroblasts express EP₃ receptor mRNA as well as EP₂ and EP₄ receptor mRNAs (Yoshida *et al.*, 2001). Thus, it is conceivable that the expression of EP receptor mRNAs in synovial fibroblasts may be affected by the condition of diseases or the medical application for donors. We also found that the expression of mRNA encoding EP₂ and EP₄ mRNAs was up-regulated by IL-1 β treatment in both OA and RA fibroblasts. IL-1 β is known to augment EP₁ receptor level, as well as PGE₂ production, in amnion cells (Spaziani *et al.*, 1997). However, in the present study, the induction of mRNA encoding EP₁ receptor by IL-1 β was not observed in synovial fibroblasts. In addition, specific agonists for EP₂ and EP₄ receptors excluding EP₁ and EP₃ receptors enhanced IL-6 and VEGF

production, and attenuated M-CSF production by fibroblasts stimulated with IL-1 β in the presence of NS-398. Moreover, there was no difference in the effects of EP receptor agonists between OA and RA fibroblasts. These findings suggest that both EP₂ and EP₄ receptors may participate in the regulation of IL-1 β -induced IL-6, M-CSF, and VEGF production in human synovial fibroblasts. Additionally, it seems likely that an increase in expression of mRNA encoding EP₂ and EP₄ receptors contributes to the PGE₂ effects in this model. Recently, PGE₂ has been found to induce parathyroid hormone-related peptide *via* EP₂ and EP₄ receptors in RA fibroblasts treated with IL-1 α (Yoshida *et al.*, 2001). Others have reported that while EP₃ receptors mediate the production of matrix metalloproteinase-9 in response to PGE₂ (Zeng *et al.*, 1996), EP₂ and EP₄ receptors regulate the production of IL-6 by PGE₂ in human leukemic T cells (Zeng *et al.*, 1998) and mediate the modulation of TNF- α -induced M-CSF synthesis by PGE₂ in human bone marrow stromal cells (Besse *et al.*, 1999). Furthermore, PGE₂ is shown to down-regulate adhesion molecule-1 expression by interferon- γ *via* EP₂ receptor in human gingival fibroblasts (Noguchi *et al.*, 1999). Expression of VEGF mRNA by PGE₂ in synovial fibroblasts has been suggested to be related to the activation of EP₂ receptor (Ben-Av *et al.*, 1995). It has also been shown that the augmentation of IL-6 production is mediated mainly by EP₂ receptor whereas the suppression of TNF- α production is predominantly regulated by EP₄ receptor in lipopolysaccharide-stimulated mouse neutrophils (Yamane *et al.*, 2000). These reports indicate that EP₂ and EP₄ receptors mediate the production of soluble factors in cells through cyclic AMP dependent-mechanism. Accordingly, we examined whether cyclic AMP contributes to the regulation by PGE₂ of the production of IL-6, M-CSF, and VEGF in synovial fibroblasts.

PGE₂ is known to stimulate cyclic AMP accumulation in Swiss 3T3 fibroblasts (Burch *et al.*, 1989). In the present study, the cyclic AMP analogues, 8-bromo-cyclic AMP and dibutyryl-cyclic AMP, themselves increased spontaneous levels of IL-6 and VEGF but reduced M-CSF level in OA fibroblasts. Furthermore, the cyclic AMP analogues mimicked the effects of PGE₂ on the production of soluble factors by IL-1 β , indicating that cyclic AMP is involved as a second messenger in the PGE₂ effects. This is further supported by the finding that pentoxifylline, a non-selective phosphodiesterase inhibitor, also enhanced VEGF production and attenuated M-CSF production by fibroblasts stimulated with IL-1 β . EP₂ and EP₄ receptors generate cyclic AMP production through stimulation of adenylyl cyclase (Coleman *et al.*, 1994; Negishi *et al.*, 1995). In fact, it has been reported that the EP₂ receptor agonist ONO-AE1-259 and the EP₄ receptor agonist ONO-AE1-329, as well as PGE₂, increase cyclic AMP formation (Yamane *et al.*, 2000). It is therefore, well possible that cyclic AMP accumulation facilitates the process of IL-6 and VEGF production and interferes with that of M-CSF production in synovial fibroblasts, although the potentiation by PGE₂ of IgE-induced IL-6 and GM-CSF production in rodent mast cells is mediated *via* EP₁ and/or EP₃ receptors with cyclic AMP-independent mechanisms (Gomi *et al.*, 2000). Furthermore, the activation of cyclic AMP-dependent protein kinase A by EP₂ and EP₄ receptors may mediate the signals for the PGE₂

effects (Ben-Av *et al.*, 1995; Zeng *et al.*, 1998; Suzawa *et al.*, 2000). However, the signalling pathways after cyclic AMP accumulation leading to the PGE₂ regulation on the production of IL-6, M-CSF, and VEGF in response to IL-1 β remain to be examined.

In conclusion, we have demonstrated for the first time that endogenous PGE₂ regulates, at least in part, the production of IL-6, M-CSF, and VEGF by IL-1 β through the activation of EP₂ and EP₄ receptors in synovial fibroblasts from patients with OA and RA. This implies that in addition to the

function of inflammatory mediator, PGE₂ plays an important role as a regulator in the production of various soluble factors at inflammatory sites.

The authors thank Ono Pharmaceutical Co. Ltd. (Osaka, Japan) for providing us with PGE₂ receptor subtype agonists such as ONO-DI-004, ONO-AE1-259, ONO-AE-248, and ONO-AE1-329. We would also like to acknowledge Dr. T. Sato, Minophagen Research Laboratory, for professional help.

References

- AGRO, A., LANGDON, C., SMITH, F. & RICHARDS, C.D. (1996). Prostaglandin E₂ enhances interleukin 8 (IL-8) and IL-6 but inhibits GM-CSF production by IL-1 stimulated human synovial fibroblasts in vitro. *J. Rheumatol.*, **23**, 862–868.
- BEN-AV, P., CROFFORD, L.J., WILDER, R.L. & HLA, T. (1995). Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. *FEBS Lett.*, **372**, 83–87.
- BESSE, A., TRIMOREAU, F., FAUCHER, J.L., PRALORAN, V. & DENIZOT, Y. (1999). Prostaglandin E₂ regulates macrophage colony stimulating factor secretion by human bone marrow stromal cells. *Biochim. Biophys. Acta.*, **1450**, 441–451.
- BURCH, R.M., WHITE, M.F. & CONNOR, J.R. (1989). Interleukin 1 stimulates prostaglandin synthesis and cyclic AMP accumulation in Swiss 3T3 fibroblasts: interactions between two second messenger systems. *J. Cell Physiol.*, **139**, 29–33.
- BUTLER, D.M., PICCOLI, D.S., HART, P.H. & HAMILTON, J.A. (1988). Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. *J. Rheumatol.*, **15**, 1463–1470.
- COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994). International union of pharmacological classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol. Rev.*, **46**, 205–229.
- CROFFORD, L.J., WILDER, R.L., RISTIMAKI, A.P., SANO, R., REMMERS, E.F., EPPS, H.R. & HLA, T. (1994). Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 β , phorbol ester, and corticosteroids. *J. Clin. Invest.*, **93**, 1095–1101.
- DAYER, J.M., DE ROCHEMONTEIX, B., BURRUS, B., DEMCZUK, S. & DINARELLO, C.A. (1986). Human recombinant interleukin-1 stimulates collagenase and prostaglandin E₂ production by human synovial cells. *J. Clin. Invest.*, **77**, 645–648.
- DEWITT, D.L. (1991). Prostaglandin endoperoxide synthase: regulation of enzyme express. *Biochim. Biophys. Acta*, **1083**, 121–134.
- FELDMANN, M., BRENNAN, F.M. & MAINI, R.N. (1996). Role of cytokines in rheumatoid arthritis. *Annu. Rev. Immunol.*, **14**, 397–440.
- FIDLER, I.J. & ELLIS, L.M. (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. *Cell*, **79**, 185–188.
- FOLKMAN, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nature Med.*, **1**, 27–31.
- FUTAKI, N., TAKAHASHI, S., YOKOYAMA, M., ARAI, I., HIGUCHI, S. & OTOMO, S. (1994). NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. *Prostaglandins*, **47**, 55–59.
- GOMI, K., ZHU, F.-G. & MARSHALL, J.S. (2000). Prostaglandin E₂ selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP₁/EP₃-dependent mechanism. *J. Immunol.*, **165**, 6545–6552.
- GUERNE, P.A., ZURAW, B.L., VAUGHAN, J.H., CARSON, D.A. & LOTZ, M. (1989). Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. *J. Clin. Invest.*, **83**, 585–592.
- HULKOWER, K.I., WERTHEIMER, S.J., LEVIN, W., COFFEY, J.W., ANDERSON, C.M., CHEN, T., DEWITT, D.L., CROWL, R.M., HOPE, W.C. & MORGAN, D.W. (1994). Interleukin-1 β induces cytosolic phospholipase A₂ and prostaglandin H synthase in rheumatoid synovial fibroblasts: Evidence for their roles in the production of prostaglandin E₂. *Arthritis Rheum.*, **37**, 653–661.
- INOUE, H., TAKAMORI, M., NAGATA, N., NISHIKAWA, T., ODA, H., YAMAMOTO, S. & KOSHIHARA, Y. (2001). An investigation of cell proliferation and soluble mediators induced by interleukin 1 β in human synovial fibroblasts: comparative response of osteoarthritis and rheumatoid arthritis. *Inflamm. Res.*, **50**, 65–72.
- ISOMAKI, P. & PUNNONEN, J. (1997). Pro- and anti-inflammatory cytokines in rheumatoid arthritis. *Ann. Medicine*, **29**, 499–507.
- JACKSON, J.R., MINTON, J.A., HO, M.L., WEI, N. & WINKLER, J.D. (1997). Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1 β . *J. Rheumatol.*, **24**, 1253–1259.
- KUNKEL, S.L., SPENGLER, K., MAY, M.A., SPENGLER, R., LAR-RICK, J. & REMICK, D. (1988). Prostaglandin E₂ regulates macrophage-derived tumor necrosis factor gene expression. *J. Biol. Chem.*, **263**, 5380–5384.
- LEE, M.-T., KAUSHANSKY, K., RALPH, P. & LADNER, M.B. (1990). Differential expression of M-CSF, G-CSF, and GM-CSF by human monocytes. *J. Leukocyte Biol.*, **47**, 275–282.
- LIU, X.-H., KIRSCHENBAUM, A., YAO, S., STEARNS, M.E., HOLLAND, J.F., CLAFFEY, K. & LEVINE, A.C. (1999). Upregulation of vascular endothelial growth factor by cobalt chloride-stimulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. *Clinic. Exp. Metastasis*, **17**, 687–694.
- MINO, T., SUGIYAMA, E., TAKI, H., KURODA, A., YAMASHITA, N., MARUYAMA, M. & KOBAYASHI, M. (1998). Interleukin-1 α and tumor necrosis factor α synergistically stimulate prostaglandin E₂-dependent production of interleukin-11 in rheumatoid synovial fibroblasts. *Arthritis Rheum.*, **41**, 2004–2013.
- MOSS, S.T. & HAMILTON, J.A. (2000). Proliferation of a subpopulation of human peripheral blood monocytes in the presence of colony stimulating factors may contribute to the inflammatory process in diseases such as rheumatoid arthritis. *Immunobiology*, **202**, 18–25.
- NAGASHIMA, M., YOSHINO, S., ISHIKAWA, T. & ASANO, G. (1995). Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. *J. Rheumatol.*, **22**, 1624–1630.
- NEGISHI, M., SUGIMOTO, Y. & ICHIKAWA, A. (1995). Prostaglandin E receptors. *J. Lipid. Mediators Cell Signal.*, **12**, 379–391.
- NOGUCHI, K., IWASAKI, K., SHITASHIGE, M., MURATO, S. & ISHIKAWA, I. (1999). Prostaglandin E₂ downregulates interferon- γ -induced intercellular adhesion molecule-1 expression via EP₂ receptors in human gingival fibroblasts. *Inflammation*, **23**, 481–493.
- ROBINSON, D.R., MCGUIRE, M.B. & LEVINE, L. (1975). Prostaglandins in the rheumatic diseases. *Ann. NY. Acad. Sci.*, **256**, 318–329.

- SIEGLE, I., KLEIN, T., BACKMAN, J.T., SAAL, J.G., MUSING, R.M. & FRITZ, P. (1998). Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. *Arthritis Rheum.*, **41**, 122–129.
- SPAZIANI, E.P., TSIBRIS, J.C.M., HUNT, L.T., BENOIT, R.R. & O'BRIEN, W.F. (1997). The effect of interleukin-1 β and interleukin-4 on the expression of prostaglandin receptors EP1 and EP3 in amnion WISH cells. *Am. J. Reprod. Immunol.*, **38**, 279–285.
- STANFORD, S.J., PEPPER, J.R. & MITCHELL, J.A. (2000). Release of GM-CSF and G-CSF by human arterial and venous smooth muscle cells: differential regulation by COX-2. *Br. J. Pharmacol.*, **129**, 835–838.
- SUZAWA, T., MIYAUURA, C., INADA, M., MARUYAMA, T., SUGIMOTO, Y., USHIKUBI, F., ICHIKAWA, A., NARUMIYA, S. & SUDA, T. (2000). The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. *Endocrinology*, **141**, 1554–1559.
- TAKAYANAGI, H., ODA, H., YAMAMOTO, S., KAWAGUCHI, H., TANAKA, S., NISHIKAWA, T. & KOSHIHARA, Y. (1997). A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. *Biochem. Biophys. Res. Commun.*, **240**, 279–286.
- WARD, A. & CLISSOLD, S.P. (1987). Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. *Drugs*, **34**, 50–97.
- WESTACOTT, C.I. & SHARIF, M. (1996). Cytokines in osteoarthritis: mediators or markers of joint destruction? *Semin. Arthritis Rheum.*, **25**, 254–272.
- XIE, W.L., CHIPMAN, J.G., ROBERTSON, D.L., ERIKSON, R.L. & SIMMONS, D.L. (1991). Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc. Natl. Acad. Sci. USA.*, **88**, 2692–2696.
- YAMANE, H., SUGIMOTO, Y., TANAKA, S. & ICHIKAWA, A. (2000). Prostaglandin E₂ receptors, EP2 and EP4, differentially modulate TNF- α and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. *Biochem. Biophys. Res. Commun.*, **278**, 224–228.
- YOSHIDA, T., HORIUCHI, T., SAKAMOTO, H., INOUE, H., TAKAYANAGAI, H., NISHIKAWA, T., YAMAMOTO, S. & KOSHIHARA, Y. (1998). Production of parathyroid hormone-related peptide by synovial fibroblasts in human osteoarthritis. *FEBS Lett.*, **433**, 331–334.
- YOSHIDA, T., SAKAMOTO, H., HORIUCHI, T., YAMAMOTO, S., SUEMATU, A., ODA, H. & KOSHIHARA, Y. (2001). Involvement of prostaglandin E₂ in interleukin-1 α -induced parathyroid hormone-related peptide production in synovial fibroblasts of patients with rheumatoid arthritis. *J. Clin. Endocrinol. Metab.*, **86**, 3272–3278.
- ZACHAROWSKI, K., OLBRICH, A., PIPER, J., HAFNER, G., KONDO, K. & THIEMERMANN, C. (1999). Selective activation of the prostanoid EP₃ receptor reduces myocardial infarct size in Rodents. *Arterioscler. Thromb. Vasc. Biol.*, **19**, 2141–2147.
- ZENG, L., AN, S. & GOETZL, E.J. (1996). Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP₃ subtype of prostaglandin E₂ receptor. *J. Biol. Chem.*, **271**, 27744–27750.
- ZENG, L., AN, S. & GOETZL, E.J. (1998). EP₄/EP₂ receptor-specific prostaglandin E₂ regulation of interleukin-6 generation by human HSB.2 early T cells. *J. Pharm. Exp. Ther.*, **286**, 1420–1426.

(Received October 8, 2001

Revised February 5, 2002

Accepted February 28, 2002)